Autoimmune 0 10 0 10 B-chronic_disease
disease 11 18 11 18 I-chronic_disease
with 19 23 19 23 O
the 24 27 24 27 O
exception 28 37 28 37 O
of 38 40 38 40 O
controlled 41 51 41 51 O
/ 51 52 51 52 O
treated 52 59 52 59 O
hypothyroidism 60 74 60 74 B-chronic_disease
, 74 75 74 75 O
disease 76 83 76 83 O
- 83 84 83 84 O
related 84 91 84 91 O
immune 92 98 92 98 B-chronic_disease
thrombocytopenic 99 115 99 115 I-chronic_disease
purpura 116 123 116 123 I-chronic_disease
, 123 124 123 124 O
or 125 127 125 127 O
hemolytic 128 137 128 137 B-chronic_disease
anemia 138 144 138 144 I-chronic_disease

Autologous 0 10 145 155 B-treatment
stem 11 15 156 160 I-treatment
cell 16 20 161 165 I-treatment
transplantation 21 36 166 181 I-treatment
( 37 38 182 183 I-treatment
SCT 38 41 183 186 I-treatment
) 41 42 186 187 I-treatment
within 43 49 188 194 O
100 50 53 195 198 B-upper_bound
days 54 58 199 203 I-upper_bound
prior 59 64 204 209 I-upper_bound
to 65 67 210 212 O
study 68 73 213 218 B-treatment
drug 74 78 219 223 I-treatment
, 78 79 223 224 O
or 80 82 225 227 O
any 83 86 228 231 O
prior 87 92 232 237 B-treatment
allogeneic 93 103 238 248 I-treatment
SCT 104 107 249 252 I-treatment
or 108 110 253 255 O
solid 111 116 256 261 B-treatment
organ 117 122 262 267 I-treatment
transplantation 123 138 268 283 I-treatment

B 0 1 284 285 B-cancer
- 1 2 285 286 I-cancer
cell 2 6 286 290 I-cancer
hematologic 7 18 291 302 I-cancer
malignancies 19 31 303 315 I-cancer
expected 32 40 316 324 O
to 41 43 325 327 O
express 44 51 328 335 O
the 52 55 336 339 O
cluster 56 63 340 347 O
of 64 66 348 350 O
differentiation 67 82 351 366 O
20 83 85 367 369 O
( 86 87 370 371 O
CD20 87 91 371 375 O
) 91 92 375 376 O
antigen 93 100 377 384 O
who 101 104 385 388 O
have 105 109 389 393 O
relapsed 110 118 394 402 O
after 119 124 403 408 O
or 125 127 409 411 O
failed 128 134 412 418 O
to 135 137 419 421 O
respond 138 145 422 429 O
to 146 148 430 432 O
at 149 151 433 435 O
least 152 157 436 441 O
one 158 161 442 445 B-lower_bound
prior 162 167 446 451 B-treatment
treatment 168 177 452 461 I-treatment
regimen 178 185 462 469 I-treatment
and 186 189 470 473 O
for 190 193 474 477 O
whom 194 198 478 482 O
there 199 204 483 488 O
is 205 207 489 491 O
no 208 210 492 494 O
available 211 220 495 504 O
therapy 221 228 505 512 B-treatment
expected 229 237 513 521 O
to 238 240 522 524 O
improve 241 248 525 532 O
survival 249 257 533 541 O

Eastern 0 7 542 549 B-clinical_variable
Cooperative 8 19 550 561 I-clinical_variable
Oncology 20 28 562 570 I-clinical_variable
Group 29 34 571 576 I-clinical_variable
( 35 36 577 578 I-clinical_variable
ECOG 36 40 578 582 I-clinical_variable
) 40 41 582 583 I-clinical_variable
performance 42 53 584 595 I-clinical_variable
status 54 60 596 602 I-clinical_variable
of 61 63 603 605 O
0 64 65 606 607 B-lower_bound
or 66 68 608 610 O
1 69 70 611 612 B-upper_bound

Hepatitis 0 9 613 622 B-chronic_disease
B 10 11 623 624 I-chronic_disease
or 12 14 625 627 I-chronic_disease
C 15 16 628 629 I-chronic_disease
or 17 19 630 632 O
human 20 25 633 638 B-chronic_disease
immunodeficiency 26 42 639 655 I-chronic_disease
virus 43 48 656 661 I-chronic_disease
( 49 50 662 663 I-chronic_disease
HIV 50 53 663 666 I-chronic_disease
) 53 54 666 667 I-chronic_disease

History 0 7 668 675 O
of 8 10 676 678 O
central 11 18 679 686 B-cancer
nervous 19 26 687 694 I-cancer
system 27 33 695 701 I-cancer
( 34 35 702 703 I-cancer
CNS 35 38 703 706 I-cancer
) 38 39 706 707 I-cancer
lymphoma 40 48 708 716 I-cancer
or 49 51 717 719 O
other 52 57 720 725 O
CNS 58 61 726 729 B-chronic_disease
disease 62 69 730 737 I-chronic_disease

Monoclonal 0 10 738 748 B-treatment
antibody 11 19 749 757 I-treatment
, 19 20 757 758 O
radioimmunoconjugate 21 41 759 779 B-treatment
, 41 42 779 780 O
antibody 43 51 781 789 B-treatment
- 51 52 789 790 I-treatment
drug 52 56 790 794 I-treatment
conjugate 57 66 795 804 I-treatment
, 66 67 804 805 O
chemotherapy 68 80 806 818 B-treatment
, 80 81 818 819 O
or 82 84 820 822 O
other 85 90 823 828 O
investigational 91 106 829 844 B-treatment
anti 107 111 845 849 I-treatment
- 111 112 849 850 I-treatment
cancer 112 118 850 856 I-treatment
agent 119 124 857 862 I-treatment
within 125 131 863 869 O
4 132 133 870 871 B-upper_bound
weeks 134 139 872 877 I-upper_bound
prior 140 145 878 883 I-upper_bound
to 146 148 884 886 O
study 149 154 887 892 B-treatment
drug 155 159 893 897 I-treatment

Pregnant 0 8 898 906 B-pregnancy

Prior 0 5 907 912 B-treatment
treatment 6 15 913 922 I-treatment
with 16 20 923 927 I-treatment
chimeric 21 29 928 936 I-treatment
antigen 30 37 937 944 I-treatment
receptor 38 46 945 953 I-treatment
T 47 48 954 955 I-treatment
- 48 49 955 956 I-treatment
cell 49 53 956 960 I-treatment
( 54 55 961 962 I-treatment
CAR 55 58 962 965 I-treatment
- 58 59 965 966 I-treatment
T 59 60 966 967 I-treatment
) 60 61 967 968 I-treatment
therapy 62 69 969 976 I-treatment
within 70 76 977 983 O
30 77 79 984 986 B-upper_bound
days 80 84 987 991 I-upper_bound
before 85 91 992 998 O
first 92 97 999 1004 O
BTCT4465A 98 107 1005 1014 B-treatment
( 108 109 1015 1016 I-treatment
Mosunetuzumab 109 122 1016 1029 I-treatment
) 122 123 1029 1030 I-treatment
administration 124 138 1031 1045 O

Receipt 0 7 1046 1053 O
of 8 10 1054 1056 O
a 11 12 1057 1058 O
live 13 17 1059 1063 B-treatment
attenuated 18 28 1064 1074 I-treatment
vaccine 29 36 1075 1082 I-treatment
within 37 43 1083 1089 O
4 44 45 1090 1091 B-upper_bound
weeks 46 51 1092 1097 I-upper_bound
prior 52 57 1098 1103 I-upper_bound
to 58 60 1104 1106 O
study 61 66 1107 1112 O
drug 67 71 1113 1117 O

Significant 0 11 1118 1129 O
cardiovascular 12 26 1130 1144 B-chronic_disease
or 27 29 1145 1147 O
pulmonary 30 39 1148 1157 B-chronic_disease
disease 40 47 1158 1165 I-chronic_disease

Systemic 0 8 1166 1174 B-treatment
immunosuppressive 9 26 1175 1192 I-treatment
medication 27 37 1193 1203 I-treatment
within 38 44 1204 1210 O
2 45 46 1211 1212 B-upper_bound
weeks 47 52 1213 1218 I-upper_bound
prior 53 58 1219 1224 I-upper_bound
to 59 61 1225 1227 O
study 62 67 1228 1233 O
drug 68 72 1234 1238 O

Treatment 0 9 1239 1248 B-treatment
with 10 14 1249 1253 I-treatment
radiotherapy 15 27 1254 1266 I-treatment
within 28 34 1267 1273 O
2 35 36 1274 1275 B-upper_bound
weeks 37 42 1276 1281 I-upper_bound
prior 43 48 1282 1287 I-upper_bound
to 49 51 1288 1290 O
the 52 55 1291 1294 O
first 56 61 1295 1300 O
BTCT4465A 62 71 1301 1310 B-treatment
( 72 73 1311 1312 O
Mosunetuzumab 73 86 1312 1325 B-treatment
) 86 87 1325 1326 O
administration 88 102 1327 1341 O

lactating 0 9 1342 1351 O
women 10 15 1352 1357 B-gender

